Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Vigil Neuroscience, Inc. (NASDAQ:VIGL) on Wednesday disclosed that it entered a deal to be acquired by Sanofi (NASDAQ:SNY) ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

Vigil on Wednesday said it is ending a Phase 2 study of iluzanebart in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, or ALSP, after the drug showed no ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Sanofi SAN-5.48%decrease; red down pointing triangle said it entered an agreement to acquire Vigil Neuroscience VIGL-0.13%decrease; red down pointing triangle for approximately $470 million ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...